PODD · 10-Q · 2026Q3 · Full report

Omnipod Product Development

INSULET CORP · 2026-11-04 · Importance 31 · Surprise 42

Insulet continued investment in Omnipod and pipeline products during the nine months ended September 30, 2026. Named development programs include Omnipod 6, described as the next-generation automated insulin delivery (AID) system, and a fully closed-loop AID system for type 2 diabetes. The filing does not provide launch timing or market-size estimates for these programs.

Key facts

• Insulet completed enrollment in the EVOLVE pivotal study for its fully closed-loop AID system for people with type 2 diabetes; the study is intended to support a planned 510(k) submission in 2027. source
• Insulet is progressing development of Omnipod 6, its next-generation automated insulin delivery system, and completed enrollment for the type 1 diabetes cohort in the STRIVE 2 study. source
• R&D expense growth in both periods primarily reflected continued investment in Omnipod and pipeline products, including Omnipod 6, a next-generation AID system, and a fully closed-loop AID system for type 2 diabetes, partly offset by lower expected incentive compensation. source